FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379284489> ?p ?o ?g. }

• W4379284489 endingPage "e13073" @default.
• W4379284489 startingPage "e13073" @default.
• W4379284489 abstract "e13073 Background: Cyclin kinase inhibitors (CDKi) are the standard of care in the first line of luminal (Lum) metastatic breast cancer (MBC). HER2 overexpression is a classic risk factor in BC, however, the use of targeted therapy has changed the prognosis of this disease, even with anti-HER2 efficacy data in cases of low HER2 expression. We wonder if the level of HER2 expression can be a predictor of efficacy in treatment with CDKi. Methods: Descriptive, observational, retrospective and analytical study of patients with MBC treated with CDKi, in the period 2018-2022. Descriptive and analytical statistical analysis (IBM SPSS Statistics 22) using logistic regression and Kaplan-Meier with long-rank test to analyze the relationship between CKi efficacy and HER2 expression (negative = 0+; HER2 low = 1+ and 2 + with SISH negative). Results: We analyzed 152 patients (p) with Lum MBC under treatment with CDKi (median 58 years), in first and successive lines. HER2 expression: 31% 46p (0+), 54% 81p (1+) and 14% 21p (2+ and SISH negative). 41% were treated with palbociclib, 34% with ribociclib, and 26% with abemaciclib. Radiological response (RR) to CDKi was achieved by 34.1% (CRR 2.4%, PRR 31.7), and the rest stable disease (SD) or progressive disease (PD): SD 42% and PD 22%. In the overall OR, there was no evidence of a risk association between the response to CDKi and the level of HER2 expression. We obtained similar results in the analysis stratified by type of CDKi. In the multivariate study, for the variables CDKi type and HER2 expression, the logistic regression model was not statistically significant either. Regarding the Kaplan-Meier analysis, we compared the median PFS and OS using the Long-rank test, based on the expression of HER2. In the complete series we did not find statistically significant differences between the curves. In the palbociclib subgroup the curves split in favor of HER2 0+ vs. HER2 low: 44 months 95%CI (7.6-80) vs 16 months 95%CI (7.9-24); p = 0.01. Regarding OS, we found no significant differences. With ribociclib, the curves separate in favor of HER2 low versus HER2 0+: 33 months 95%CI (7.2-18) vs. 13 months 95%CI (23-42); p = 0.03. In OS we did not find significant differences either. In the subgroup with abemaciclib, we observed a trend towards greater survival in HER2 0+ patients, but with no significant difference between the PFS or OS curves. Conclusions: Based on our study, the expression of HER2 could be considered a predictor of efficacy depending on the CDKi used. We assume greater survival with palbociclib in HER2 negative patients (0+) and with ribociclib in HER2 low patients. We consider it essential to develop studies with a larger sample size and clinical trials that allow us to demonstrate the hypothesis of our work with scientific evidence." @default.
• W4379284489 created "2023-06-05" @default.
• W4379284489 creator A5004710847 @default.
• W4379284489 creator A5050592034 @default.
• W4379284489 creator A5065608893 @default.
• W4379284489 creator A5085885327 @default.
• W4379284489 date "2023-06-01" @default.
• W4379284489 modified "2023-10-17" @default.
• W4379284489 title "Is HER2 expression related to CDKi efficacy in HER2-negative luminal metastatic breast cancer?" @default.
• W4379284489 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e13073" @default.
• W4379284489 hasPublicationYear "2023" @default.
• W4379284489 type Work @default.
• W4379284489 citedByCount "0" @default.
• W4379284489 crossrefType "journal-article" @default.
• W4379284489 hasAuthorship W4379284489A5004710847 @default.
• W4379284489 hasAuthorship W4379284489A5050592034 @default.
• W4379284489 hasAuthorship W4379284489A5065608893 @default.
• W4379284489 hasAuthorship W4379284489A5085885327 @default.
• W4379284489 hasConcept C121608353 @default.
• W4379284489 hasConcept C126322002 @default.
• W4379284489 hasConcept C143998085 @default.
• W4379284489 hasConcept C151956035 @default.
• W4379284489 hasConcept C2775930923 @default.
• W4379284489 hasConcept C2779744173 @default.
• W4379284489 hasConcept C530470458 @default.
• W4379284489 hasConcept C71924100 @default.
• W4379284489 hasConceptScore W4379284489C121608353 @default.
• W4379284489 hasConceptScore W4379284489C126322002 @default.
• W4379284489 hasConceptScore W4379284489C143998085 @default.
• W4379284489 hasConceptScore W4379284489C151956035 @default.
• W4379284489 hasConceptScore W4379284489C2775930923 @default.
• W4379284489 hasConceptScore W4379284489C2779744173 @default.
• W4379284489 hasConceptScore W4379284489C530470458 @default.
• W4379284489 hasConceptScore W4379284489C71924100 @default.
• W4379284489 hasIssue "16_suppl" @default.
• W4379284489 hasLocation W43792844891 @default.
• W4379284489 hasOpenAccess W4379284489 @default.
• W4379284489 hasPrimaryLocation W43792844891 @default.
• W4379284489 hasRelatedWork W2769683585 @default.
• W4379284489 hasRelatedWork W2912763149 @default.
• W4379284489 hasRelatedWork W3044815817 @default.
• W4379284489 hasRelatedWork W3092326212 @default.
• W4379284489 hasRelatedWork W3203106735 @default.
• W4379284489 hasRelatedWork W3203690439 @default.
• W4379284489 hasRelatedWork W4210295521 @default.
• W4379284489 hasRelatedWork W4283528480 @default.
• W4379284489 hasRelatedWork W4367835219 @default.
• W4379284489 hasRelatedWork W4379054559 @default.
• W4379284489 hasVolume "41" @default.
• W4379284489 isParatext "false" @default.
• W4379284489 isRetracted "false" @default.
• W4379284489 workType "article" @default.